X4 Pharmaceuticals Inc (XFOR) Unusual Options Activity Today

Checking XFOR unusual options activity helps you spot when traders are making outsized bets on X4 Pharmaceuticals Inc before the broader market catches on. X4 Pharmaceuticals Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor XFOR unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching XFOR unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking XFOR unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and XFOR unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd.

grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.

Catalysts rarely arrive without a footprint, and XFOR unusual options activity is often where that footprint shows up first. Our scanner tracks X4 Pharmaceuticals Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at XFOR unusual options volume on the call side or chasing put sweeps, X4 Pharmaceuticals Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.